Abstract
A series of 7,8-dihydroxy-4-arylcoumarins, the derivatives related to DW532 that was an anti-tumor agent targeting both kinase and tubulin, was prepared by Suzuki coupling reaction. Among them, compounds 6a, 6b, and 6c were found to exhibit anti-proliferation activities against human breast carcinoma MDA-MB-468 cells with IC50 values of 0.64, 0.69, and 1.33 μM, respectively and human epidermoid carcinoma A431 cells with IC50 values of 2.56, 1.78, and 2.29 μM, respectively. Further evaluation of the selected molecules revealed that they displayed broad-spectrum inhibitory activities against a panel of kinases including Flt-1, VEGFR2, RET, EGFR, etc. In vitro tubulin polymerization assay and molecular docking indicated that the substitution of 3’-OH and 4’-OCH3 on the 4-phenyl ring was essential to achieve potent tubulin inhibition.
Keywords: Anticancer, 4-Arylcoumarin, Cytotoxicity, Structure-activity relationship, Tubulin, Tyrosine kinase inhibition.
Letters in Drug Design & Discovery
Title:Synthesis and Anticancer Activity of 7,8-dihydroxy-4-arylcoumarins
Volume: 12 Issue: 5
Author(s): Jianrui Wu, Ting Peng, Fang Chen, Yixin Leng, Linjiang Tong, Mengyuan Li, Rong Qu, Hua Xie, Jian Ding and Wenhu Duan
Affiliation:
Keywords: Anticancer, 4-Arylcoumarin, Cytotoxicity, Structure-activity relationship, Tubulin, Tyrosine kinase inhibition.
Abstract: A series of 7,8-dihydroxy-4-arylcoumarins, the derivatives related to DW532 that was an anti-tumor agent targeting both kinase and tubulin, was prepared by Suzuki coupling reaction. Among them, compounds 6a, 6b, and 6c were found to exhibit anti-proliferation activities against human breast carcinoma MDA-MB-468 cells with IC50 values of 0.64, 0.69, and 1.33 μM, respectively and human epidermoid carcinoma A431 cells with IC50 values of 2.56, 1.78, and 2.29 μM, respectively. Further evaluation of the selected molecules revealed that they displayed broad-spectrum inhibitory activities against a panel of kinases including Flt-1, VEGFR2, RET, EGFR, etc. In vitro tubulin polymerization assay and molecular docking indicated that the substitution of 3’-OH and 4’-OCH3 on the 4-phenyl ring was essential to achieve potent tubulin inhibition.
Export Options
About this article
Cite this article as:
Wu Jianrui, Peng Ting, Chen Fang, Leng Yixin, Tong Linjiang, Li Mengyuan, Qu Rong, Xie Hua, Ding Jian and Duan Wenhu, Synthesis and Anticancer Activity of 7,8-dihydroxy-4-arylcoumarins, Letters in Drug Design & Discovery 2015; 12 (5) . https://dx.doi.org/10.2174/1570180812666141111235026
DOI https://dx.doi.org/10.2174/1570180812666141111235026 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cellular Uptake and Apoptotic Efficiency of Colchicine is Correlated with Downregulation of MMP-9 mRNA Expression in SW480 Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Synthesis of New Curcumin-like Pentadienones by O- and C-glycosylation
Current Organic Chemistry Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Pharmaceutical Nanotechnology Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews ER Stress and Autophagy
Current Molecular Medicine The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Analysis of Performance of Two Wavelet Families Using GLCM Feature Extraction for Mammogram Classification of Breast Cancer
Recent Advances in Computer Science and Communications The-N-End Rule: The Beginning Determines the End
Protein & Peptide Letters Nanotechnologies in Agriculture and Food - an Overview of Different Fields of Application, Risk Assessment and Public Perception
Recent Patents on Food, Nutrition & Agriculture